NGNE
Neurogene Inc.
Key Financials
Operating Income
$-103328000
↓ 25.1%
Revenue
$0
↓ 100.0%
Net Income
$-90351000
↓ 20.2%
Total Liabilities
$23.7M
↓ 6.5%
EPS (Diluted)
$-4.24
↑ 0.9%
Shareholders' Equity
$264.9M
↓ 14.7%
Total Assets
$288.6M
↓ 14.0%
Operating Cash Flow
$-77173000.00
↓ 9.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G | 8/14/2026 | View on SEC |
| 10-Q | 8/11/2026 | View on SEC |
| 8-K | 8/11/2026 | View on SEC |
| 4 | 7/7/2026 | View on SEC |
| 4 | 7/2/2026 | View on SEC |
| 8-K | 7/2/2026 | View on SEC |
| 424B5 | 7/2/2026 | View on SEC |
| 424B5 | 6/30/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | NGNE |
| Company Name | Neurogene Inc. |
| CIK | 1404644 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| Phone | (877) 237-5020 |